309 related articles for article (PubMed ID: 1184747)
1. Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion.
Myers CE; Young RC; Chabner BA
J Clin Invest; 1975 Nov; 56(5):1231-8. PubMed ID: 1184747
[TBL] [Abstract][Full Text] [Related]
2. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil.
Berger SH; Hakala MT
Mol Pharmacol; 1984 Mar; 25(2):303-9. PubMed ID: 6608049
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
Spears CP; Gustavsson BG; Berne M; Frösing R; Bernstein L; Hayes AA
Cancer Res; 1988 Oct; 48(20):5894-900. PubMed ID: 3167844
[TBL] [Abstract][Full Text] [Related]
4. On the rational development of a new drug: the example of the fluorinated pyrimidines.
Heidelberger C
Cancer Treat Rep; 1981; 65 Suppl 3():3-9. PubMed ID: 7346154
[TBL] [Abstract][Full Text] [Related]
5. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.
Spears CP; Shahinian AH; Moran RG; Heidelberger C; Corbett TH
Cancer Res; 1982 Feb; 42(2):450-6. PubMed ID: 6173112
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil.
Spears CP; Gustavsson BG; Mitchell MS; Spicer D; Berne M; Bernstein L; Danenberg PV
Cancer Res; 1984 Sep; 44(9):4144-50. PubMed ID: 6744325
[TBL] [Abstract][Full Text] [Related]
7. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor.
Myers CE; Young RC; Chabner BA
Cancer Res; 1976 May; 36(5):1653-8. PubMed ID: 1268826
[TBL] [Abstract][Full Text] [Related]
8. Sequential methotrexate and 5-fluorouracil: mechanisms of synergy.
Bertino JR; Mini E; Fernandes DJ
Semin Oncol; 1983 Jun; 10(2 Suppl 2):2-5. PubMed ID: 6867754
[TBL] [Abstract][Full Text] [Related]
9. Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthetase.
Moran RG; Spears CP; Heidelberger C
Proc Natl Acad Sci U S A; 1979 Mar; 76(3):1456-60. PubMed ID: 108681
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
11. [Studies on the mechanism of antitumor activity of 5-FU and its derivatives--relationship between the inhibition of tumor growth and the inhibition of thymidylate synthetase in vivo].
Nakamura H; Yu-Qin W; Miyauchi S; Nishioka N; Tanaka H; Harada N; Shirasaka T; Fujii S
Gan To Kagaku Ryoho; 1984 May; 11(5):1049-55. PubMed ID: 6426401
[TBL] [Abstract][Full Text] [Related]
12. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
[TBL] [Abstract][Full Text] [Related]
13. Biphasic binding of 5-fluoro-2'-deoxyuridylate to human thymidylate synthase.
Reilly RT; Barbour KW; Dunlap RB; Berger FG
Mol Pharmacol; 1995 Jul; 48(1):72-9. PubMed ID: 7623777
[TBL] [Abstract][Full Text] [Related]
14. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.
Houghton JA; Maroda SJ; Phillips JO; Houghton PJ
Cancer Res; 1981 Jan; 41(1):144-9. PubMed ID: 7448754
[TBL] [Abstract][Full Text] [Related]
15. Acyclic analogues of 5-fluoro-dUMP and 5-fluoro-2'-deoxyuridine: synthesis and inhibition of thymidylate synthase and tumour cell growth.
Felczak K; Gołos B; Dzik JM; Rode W; Bretner M; Shugar D; Kulikowski T
Acta Biochim Pol; 1998; 45(1):75-82. PubMed ID: 9701498
[TBL] [Abstract][Full Text] [Related]
16. Determinants of response to antimetabolites and their modulation by normal purine and pyrimidine metabolites.
Rustum YM; Danhauser L; Luccioni C; Au JL
Cancer Treat Rep; 1981; 65 Suppl 3():73-82. PubMed ID: 7049369
[TBL] [Abstract][Full Text] [Related]
17. Development, characterization and application of an antibody against 5-fluoro-2'deoxyuridine-5'monophosphate, the active metabolite of 5-fluorouracil.
Peters GJ; Laurensse E; Steinbusch HW; De Vente J; Smid K; Van der Wilt CL; Pinedo HM
Anticancer Res; 1993; 13(4):835-9. PubMed ID: 8352551
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous quantification of 5-FU, 5-FUrd, 5-FdUrd, 5-FdUMP, dUMP and TMP in cultured cell models by LC-MS/MS.
Carli D; Honorat M; Cohen S; Megherbi M; Vignal B; Dumontet C; Payen L; Guitton J
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):2937-44. PubMed ID: 19620028
[TBL] [Abstract][Full Text] [Related]
19. Deoxyuridylate effects on thymidylate synthase-5-fluorodeoxyuridylate-folate ternary complex formation.
Spears CP; Hayes AA; Shahinian AH; Danenberg PV; Frösing R; Gustavsson BG
Biochem Pharmacol; 1989 Sep; 38(18):2985-93. PubMed ID: 2783153
[TBL] [Abstract][Full Text] [Related]
20. Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas.
Houghton JA; Weiss KD; Williams LG; Torrance PM; Houghton PJ
Biochem Pharmacol; 1986 Apr; 35(8):1351-8. PubMed ID: 3008760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
